The erythrocyte binding antigen EBA-175 is a 175-kDa Plasmodium falciparum protein which mediates merozoite invasion of erythrocytes in a sialic acid-dependent manner. The purpose of this study was to produce recombinant EBA-175 polypeptide domains which have previously been identified as being involved in the interaction of EBA-175 with erythrocytes and to determine whether these polypeptides are recognized by malaria-specific antibodies. The eba-175 gene was cloned by PCR from genomic DNA isolated from the 3D7 strain of P. falciparum. The predicted protein sequence was highly conserved with that predicted from the published eba-175 gene sequences from the Camp and FCR-3 strains of P. falciparum and contained the F segment divergent region. Purified recombinant EBA-175 polypeptide fragments, expressed as glutathione S-transferase fusion proteins in insect cells by using the baculovirus system, were recognized by antibodies present in serum from a drug-cured, malaria-immune Aotus nancymai monkey. The fusion proteins were also recognized by antibodies present in sera from individuals residing in areas where malaria is endemic. In both cases the antibodies specifically recognized the EBA-175 polypeptide portion of the fusion proteins. Antibodies raised in rabbits immunized with the recombinant fusion proteins recognized parasite proteins present in schizont-infected erythrocytes. Our results suggest that these regions of the EBA-175 protein are targets for the immune response against malaria and support their further study as possible vaccine components.
Malaria is one of the most serious diseases affecting much of the world. Its prevalence is rising as the result of increased resistance of both the vector and parasite to chemical treatment. Of the four species that cause human malaria, Plasmodium falciparum accounts for approximately one million to three million deaths and hundreds of millions of additional clinical cases per year (18) . Because of this increase in drug resistance, much attention is being focused on the development of vaccines based on either single or multiple parasitederived antigens. One of these proteins, the 175-kDa erythrocyte binding antigen, EBA-175, is a parasite receptor involved in sialic acid-dependent binding to and invasion of human erythrocytes by the merozoite stage of P. falciparum (6) . EBA-175 mediates this process by interacting with the terminal NeuAc(␣2-3)Gal-moieties of glycophorin A (23, 31) . The gene encoding EBA-175 has been cloned from the Camp and FCR-3 strains of P. falciparum, and the deduced primary structures of the gene products are highly homologous (37, 42) . The major difference between the two dimorphic proteins is the presence of a small defined set of amino acid residues. The Camp EBA-175 protein contains a 113-amino-acid-residue domain called the C segment, and the FCR-3 EBA-175 protein contains a 139-residue domain designated the F segment (42) . Although these domains do not possess significant sequence homology, when expressed in vitro, they both bind to erythrocytes in a sialic acid-independent manner and contain crossreactive epitopes (20) .
A second domain of EBA-175 has also been shown to be involved in erythrocyte binding (36) . This domain, called region II (RII), consists of subdomains F1 and F2 and was first proposed to be involved in erythrocyte binding based on predicted primary sequence homology to the cysteine residue-rich erythrocyte binding domains of the Plasmodium vivax and Plasmodium knowlesi Duffy binding proteins (1) . RII and its subdomain F2, when expressed in a COS cell surface expression system, bind to human erythrocytes in a sialic acid-dependent manner, and this binding is inhibited by soluble glycophorin A (36) . An additional C-terminal cysteine-rich stretch of amino acids, region VI, has been reported to have high homology with a corresponding region of the Duffy binding proteins of P. vivax and P. knowlesi but does not bind to erythrocytes when expressed in the COS system (1, 36) .
While these studies have yielded important insights into the function of the EBA-175 protein, the difficulty of isolating sufficient amounts of purified, native EBA-175 has precluded rigorous investigation of two aspects of EBA-175-mediated invasion of erythrocytes by merozoites. The first is determination of the types of molecular interactions involved in EBA-175 protein binding to its erythrocyte ligand. Structural studies require milligram to gram quantities of protein, an amount not practically obtainable from parasite culture supernatants. The second is delineation of the domains of EBA-175 which are both immunogenic and recognized by naturally acquired malaria-specific antibodies. The purpose of this study was twofold: first, to utilize the invertebrate baculovirus expression system to express in insect cells regions of EBA-175 which have been either shown or suggested to be important for erythrocyte binding and, second, to determine if the recombinant polypep-tides are recognized by antibodies in sera obtained from regions of the world where malaria is endemic. The results of this study will facilitate identification of the domains of this important parasite ligand which will be the best candidates for inclusion in a malaria vaccine.
(A preliminary account of this work has been reported previously [10] .)
Cloning of the 3D7 eba-175 gene and construction of recombinant baculovirus transfer plasmids. Molecular cloning of parasite DNA fragments was performed by standard methods (2) . The entire DNA fragment encoding the predicted extracellular domain of EBA-175, exon I, was amplified by the PCR in three fragments with the oligonucleotide primer pairs JRD5-JRD8, JRD2-JRD4, and JRD39-JRD40 (Table 1) . The fragments were then sequentially ligated together into the plasmid pBluescript SK ϩ (Stratagene) by using the unique XbaI and EcoRI restriction endonuclease sites present in the eba-175 gene.
The plasmid transfer vectors used for construction of recombinant baculovirus have been described previously (27, 41) . The vector used for expression and secretion of the EBA-175 polypeptides as glutathione S-transferase (GST) fusions was plasmid pAcSG2T (Pharmingen, San Diego, Calif.) (38) . PCR-amplified eba-175 gene fragments were cloned into the unique BamHI and EcoRI recognition sites in plasmid pAcSG2T. This plasmid contains a nucleotide sequence that encodes the secretion signal sequence from the baculoviral P67 protein (43) . The oligonucleotide primers used for amplification of the gene fragments are shown in Table 1 . Primer pair JRD96-JRD97 was used to amplify the DNA encoding the RII(F2) region (plasmid pAcJD15; amino acid residues 461 to 753), primer pair JRD91-JRD92 was used for amplification of the F segment domain (plasmid pAcJD10; amino acid residues 776 to 916), and primer pair JRD111-JRD112 was used for amplification of the 3Ј Cys region (plasmid pAcJD25; amino acid residues 1305 to 1421) (region VI in reference 1).
The vector used for expression of the EBA-175 RII(F2) polypeptide lacking a GST tag was plasmid pJD7, a derivative of plasmid pVLBS1egt (27) . Plasmid pJD7 was constructed from pVLBS1egt by filling in the EcoRI site at nucleotide 2900 and inserting the polylinker 5Ј-KpnI PstI XbaI BamHI EcoRI NcoI NotI-3Ј at the KpnI site of the plasmid such that the 3Ј KpnI site was destroyed. The polylinker fragment consisted of annealed oligonucleotides JRD25 (5Ј-CCTGCAGTCTAGAGGATCCGAATTCCCATGGGCGGCCGCGTAC-3Ј) and JRD26 (5Ј-GCGGCCGCCCATGGGAATTCGGATCCTCTAGACTGC AGGGTAC-3Ј). Plasmid pJD7 contained a nucleotide sequence that encodes the secretion signal sequence from the baculoviral ecdysteroid UDP-glucosyl transferase (Egt) protein (30) . The DNA fragment encoding the RII(F2) domain (amino acid residues 440 to 775) was amplified by PCR with the primer pair JRD61-JRD62 and cloned into the KpnI and NotI sites in the polylinker of plasmid pJD7. The resulting construct was called plasmid pJD15.
Insect cell transfection and recombinant baculovirus construction. Cotransfections of plasmid and baculoviral DNA were performed with BacPAK6 baculoviral DNA (Clontech Laboratories, Palo Alto, Calif.) by standard methods (2) .
Expression and purification of recombinant EBA-175 polypeptides produced in insect cells. Small-scale expression of recombinant EBA-175 polypeptides was performed by standard techniques (2). Modifications were made for large-scale expression of the recombinant polypeptides. Ten-liter batches of insect cells were maintained at pH 6.2 by using a controlled bioreactor system at 27°C with a constant agitation rate of 60 rpm. The dissolved oxygen level was maintained at 50% air saturation throughout the course of the recombinant viral infection cycle. The bioreactor vessel contained a serum-free medium (Cyto-Sf9; Kemp Biotechnologies, Inc., Frederick, Md.) and was inoculated with Sf21 cells at an initial density of 2.5 ϫ 10 5 /ml. The viability of the inoculum was Ͼ90% by the trypan blue exclusion test. When the cell density reached a level of approximately 1.5 ϫ 10 6 /ml, a high-titer stock of the appropriate virus produced in Cyto-Sf9 containing 10% fetal bovine serum (Hyclone, Logan, Utah) was added at a multiplicity of infection of 1. The culture was harvested at 72 h postinfection by using centrifugation at 800 ϫ g for 5 min. The supernatant fluid was collected, and the protease inhibitor phenylmethylsulfonyl fluoride was added to a final concentration of 10 mM. The supernatant fluid was stored frozen at Ϫ20°C prior to purification. Purification of recombinant proteins. The recombinant 3Ј Cys-GST and GST were both purified in single passages over glutathione-Sepharose 4B resin chromatography columns (Pharmacia) (38) . The RII(F2)-GST and F segment-GST proteins, however, did not initially bind directly to the glutathione-Sepharose. Purification of the F segment-GST protein was achieved with a combination of Q Sepharose Fast Flow (Pharmacia), G-75 Sepharose (Pharmacia), and glutathione-Sepharose 4B chromatography. Purification of the RII(F2)-GST fusion protein required Microprep S (Bio-Rad Laboratories, Hercules, Calif.), G-75 Sepharose, and glutathione-Sepharose 4B chromatography. Details of the column chromatography procedures are available upon request. Protein concentrations were determined by the method of Bradford (3) . Purity of the recombinant proteins was approximated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie blue staining of 15 g of each purified recombinant EBA-GST fusion protein.
Aotus and human sera. Malaria-immune serum was obtained from an Aotus nancymai monkey that had been experimentally infected three times with the FVO strain of P. falciparum. Human serum samples were obtained from adults living in areas where P. falciparum is highly endemic and were pooled for use in Western blotting and enzyme-linked immunosorbent assays (ELISA).
Immunoblot analysis of secreted EBA-175 polypeptides. Cloned antigens were investigated by immunoblotting for reactivity with specific antibodies (2, 5) . Either supernatant from cultures of recombinant virus-infected Sf9 cells or purified protein was subjected to SDS-PAGE under reducing conditions. Proteins were electrophoretically transferred to polyvinylidene difluoride membrane, and the membrane was blocked overnight in blocking buffer (10% nonfat milk in 1ϫ phosphate-buffered saline). Diluted serum or horseradish peroxidase (HRP)-conjugated secondary antibody was incubated with the membrane for 1 h, and washed proteins were detected by enhanced chemiluminescence (Pierce Chemical Co., Rockford, Ill.). All reactions and washes were done at room temperature. Molecular mass standards were obtained from either Amersham or Gibco BRL.
Immunofluorescence assay (IFA). New Zealand White rabbits were immunized with 200 g of recombinant proteins mixed with 50 g of the adjuvant QS-21, and sera were obtained. Each serum sample was incubated at a 1:200 dilution with methanol-fixed 3D7 schizont-infected erythrocytes for 1 h at room temperature. The infected erythrocytes were washed and then incubated with fluorescein isothiocyanate-labeled secondary antibody for 1 h at room temperature, washed, and examined with a fluorescence microscope.
ELISA. Microtiter plates were incubated overnight with 2 g of recombinant proteins/ml at 4°C and then blocked in Blocker casein in Tris-buffered saline (Pierce) plus 0.1% Tween 20 for 1 h at room temperature. Serum specimens diluted 1:100 in casein buffer were incubated with the plates for 1 h at room temperature. Plates were washed and incubated for 1 h with an alkaline phosphatase-labeled goat anti-human immunoglobulin G (IgG) antibody. The plates were washed, and the absorbance at 405 nm was measured by kinetic ELISA every 2 min for 1 h. The results were recorded as milli-optical density per minute. All samples were run in triplicate.
Nucleotide sequence accession number. The nucleotide sequence reported in this paper has been deposited in the GenBank database under accession no. U32207.
RESULTS
Analysis of the predicted amino acid sequence of EBA-175 from the 3D7 strain and comparison with the homologous proteins from the FCR-3 and Camp strains of P. falciparum.
Sequencing of the cloned exon I of the 3D7 strain eba-175 gene (Fig. 1 ) demonstrated that it contained the F segment-encoding region and that the predicted protein sequence differed from that of the FCR-3 strain at only three positions, one located in the cysteine-rich RII domain and the other two located carboxy terminal to the RII domain ( Table 2 ). Besides the C or F segment, the predicted 3D7 EBA-175 protein sequence differed from the Camp amino acid sequence by nine residues. Six of the nine substitutions were located in the RII domain, and the other three were situated carboxy terminal to the RII domain. The 3D7 EBA-175 protein sequence contained 19 putative N-linked glycosylation sites; however, since P. falciparum has been reported to be unable to N glycosylate proteins, the significance of these sequences, if any, is unknown (12) .
Immunoreactivity of baculovirus-expressed EBA-175 polypeptides. The RII(F2)-GST, F segment-GST, 3Ј Cys-GST, and GST were expressed in insect cells, as was the RII(F2) region without a GST tag. The predicted molecular masses of the secreted recombinant fusion polypeptides are as follows: F segment-GST, 42 kDa; RII(F2)-GST, 62 kDa; RII(F2), 41 kDa; and 3Ј Cys-GST, 40 kDa. The EBA-GST proteins were all recognized by polyclonal anti-GST antibodies by immunoblotting ( Fig. 2A) . Neither the GST fusion proteins nor GST alone was present in the supernatant from an uninfected Sf9 (Fig. 2B) . Serum antibodies obtained from a rabbit immunized with peptide P8, the linear counterpart of peptide P7, showed similar reactivity by immunoblotting (data not shown). The F segment-GST fusion protein was recognized by antibodies present in serum from a rabbit immunized with peptide P3, which was derived from the F segment region of 3D7 EBA-175; GST protein alone was not (Fig. 2B) . Recognition of recombinant EBA-175 polypeptides by Aotus antibodies. As shown by immunoblotting, secreted F segment-GST, 3Ј Cys-GST, RII(F2)-GST, and nontagged RII(F2) polypeptides present in infected insect cell supernatants were all recognized by serum antibodies obtained from an A. nancymai monkey infected with the FVO strain of P. falciparum and drug cured. As expected, GST control protein was not recognized by this antiserum (Fig. 3) . Serum obtained from a malaria-naive A. nancymai monkey did not recognize the fusion proteins (data not shown). PCR and DNA fingerprint analyses have demonstrated that EBA-175 from all strains of P. falciparum tested to date contain either the F segment or the C segment dimorphic domain (42) . The observation that the F segment was recognized by the FVO-immune serum antibodies suggested that the F segment domain was present in the EBA-175 protein derived from the FVO strain. Presence of the F segment domain was confirmed by PCR analysis (data not shown).
Recognition of recombinant EBA-175 polypeptides by human antibodies. Immunoblot analysis demonstrated that the 3Ј Cys-GST, F segment-GST, RII(F2)-GST, and nontagged RII (F2) proteins present in culture supernatants were all recognized by antibodies present in pooled sera obtained from people residing in areas of Kenya and Indonesia where malaria is endemic, while GST alone was not (Fig. 4) . No specific reactivity between malaria-naive human serum antibodies and any of the recombinant EBA-175 proteins was detected (data not shown). The recombinant proteins were purified by column chromatography such that each product was more than 90% restricted to a single predicted molecular mass band as described in Materials and Methods (Fig. 5 ). An ELISA was performed to determine whether the purified recombinant EBA-GST polypeptides would react under native conditions with antibodies in human serum (Fig. 6) . The F segment-GST, RII(F2)-GST, 3Ј Cys-GST, and GST proteins all reacted to antibodies present in sera from persons residing in regions where malaria is endemic, although the reactivity with GST was in all cases lower than that seen with the EBA-GST fusion proteins. A pattern of reactivity similar to that for the RII(F2)-GST was seen with purified RII(F2) which lacked the GST moiety (data not shown).
Recognition of parasite proteins by rabbit antibodies raised against recombinant EBA-175 polypeptides. Sera collected from rabbits immunized with recombinant EBA-GST fusion proteins were assayed by IFA for the presence of antibodies which were able to recognize malarial parasite proteins (Table  3) . Serum antibodies from animals immunized with either RII(F2)-GST, F segment-GST, or 3Ј Cys-GST recombinant fusion proteins recognized parasite proteins in methanol-fixed smears of infected erythrocytes, while serum obtained from an animal which was immunized with GST alone was nonreactive. In addition, sera from animals immunized with recombinant EBA-GST proteins recognized a parasite protein with an approximate molecular mass of 175 kDa by immunoblotting, consistent with the known size of EBA-175 (data not shown).
DISCUSSION
Invasion of erythrocytes by malaria merozoites is a process that is mediated on the molecular level by multiple ligandreceptor interactions. Several proteins have been identified as being involved in this process, both on the parasite (MSP1, EBA-175, SERA, AMA-1, and a group of rhoptry proteins known as RHOP-H) and on the erythrocyte (6, 16, (32) (33) (34) . Once the molecules involved have been identified, studies can be performed to investigate the effects on erythrocyte binding and invasion by interrupting these receptor-ligand interactions. Synthesis and purification of Plasmodium proteins by recombinant methods has proved difficult, but recent advances in bacterial, yeast, and baculovirus expression systems and the addition of purification tags have yielded several of these proteins in forms pure enough for immunization studies. Regions of MSP1 have been produced in bacteria, yeast, and baculovirus (4, 7, 21, 28) . An N-terminal fragment of the SERA protein was made in yeast, and recently fragments of the SERA protein have been made in bacteria by using synthetic genes designed to mimic E. coli codon usage (19, 39) . AMA-1 has been synthesized in and purified from baculovirus-infected insect cells (29) . All of these recombinant proteins are now in vaccine trials in an attempt to induce antibodies that will block merozoite recognition of erythrocyte ligands and the subsequent invasion process through the erythrocyte membrane. Unlike these malaria antigens, to date, EBA-175 has not been produced in sufficient quantity or purity to permit detailed immunogenicity studies.
The gene encoding EBA-175 was cloned from the 3D7 strain, which is used in human malaria vaccine trials due to the strain's ability to be easily maintained in culture, its infectivity for mosquitoes, and its sensitivity to chloroquine and mefloquine (9) . DNA sequence analysis demonstrated that the predicted sequence of the 3D7 protein was highly homologous to its counterpart from the FCR-3 strain of P. falciparum. Most of the amino acid substitutions consisted of nonconserved amino acids.
The reported roles of the cysteine-rich RII, F segment, and C segment domains in binding the EBA-175 protein to human erythrocytes suggests that these regions might be targets of the immune response to infection with P. falciparum. The results of the present study demonstrate that these domains contain Bcell epitopes which are accessible to the immune system, as shown by their reactivity with Aotus and human malaria-immune sera. While the 3Ј cysteine-rich region does not bind to erythrocytes in the COS system, our results demonstrated that this region was recognized by antibodies present in the malaria-immune sera. Expression in COS cells is transient, with a transfection efficiency of 0.5 to 10%, and not all COS7 cells that express recombinant proteins bind erythrocytes (8) . Therefore, it is still possible that the 3Ј Cys domain binds erythrocytes but that the affinity of binding was too low to be detected in the COS expression system. Erythrocyte binding studies using the purified 3Ј Cys-GST protein produced in this study will be required to answer this question. It is also possible that this domain has a function other than erythrocyte binding which is not detectable in the COS system, such as signal transduction. Cysteine-rich domains have been reported to be involved in receptor-mediated signaling (15, 26) . Deletion and b Rabbits were bled prior to the first immunization with recombinant protein and again 2 weeks after the third immunization.
site-directed mutagenesis studies will help clarify this possible role in vivo.
Our results demonstrate that EBA-175 recombinant polypeptides can be efficiently produced and secreted by using a eukaryotic invertebrate expression system and that these polypeptides are recognized by antibodies in human and monkey sera following infection with P. falciparum. These proteins were recognized by antibodies made against synthetic peptides designed from the predicted coding sequences of the EBA-175 protein domains. Furthermore, immunization of animals with these recombinant EBA-GST fusion proteins elicited antibodies which recognized native schizont-infected erythrocytes, as shown by immunofluorescence. Therefore, we conclude that the recombinant proteins which we have produced each possess a structural conformation similar to that of the corresponding domains contained within native parasite EBA-175 protein.
Recognition of an antigen by the immune system does not necessarily translate to an ability to elicit protection against infection by the malaria parasite. However, the availability of these purified, soluble recombinant EBA-175 polypeptides will allow the in vitro and in vivo studies required to answer this question to be performed. These results add further support to the hypothesis that these regions of the EBA-175 protein will be effective immunogens, and thus they should be studied further for possible inclusion in a malaria vaccine (36) .
